Skip to content Skip to footer
Subscribe Now
NEWS

DualityBio Inks $1B+ Deal with Genentech to Develop Next-Generation ADCs 

Shots: DUALITYBIO has entered into a collaboration & license agreement with Genentech to develop next-generation ADCs, leveraging DUALITYBIO’s DUPAC (DualityBio Unique Payload Antibody Conjugate) platform DualityBio will discover & develop ADCs against Genentech-selected oncology targets using DUPAC payloads, leading discovery & early global development, while Genentech will secure exclusive global rights & take over development…
15 hours ago

Read more

NEWS

Natera and Angiex Partner to Monitor AGX101 Response Using Signatera

Shots: Natera has entered into collaboration with Angiex to use longitudinal Signatera testingfor circulating tumor DNA (ctDNA) to assess treatment response monitoring during AGX101 treatment AGX101 is designed to target TM4SF1-expressing tumor cells & tumor-associated endothelial cells, delivering a cytotoxic payload to both the tumor & its vasculature Angiex is conducting a P-I trial of…
4 days ago

Read more

NEWS

Osivax and GC Biopharma Partner on Next-Generation Influenza Vaccine

Shots: Osivax & GC Biopharma have entered a long-term collaboration to develop & commercialize a next-generation seasonal influenza vaccine combining OVX836, Osivax’s T-cell vaccine, with GC FLU, GC Biopharma’s WHO-prequalified seasonal flu vaccine The single-injection combination is designed to generate complementary immune responses, with T cells targeting the conserved NP antigen alongside antibodies against the…
4 days ago

Read more

NEWS

Haisco Licenses Preclinical Immunology Drug to Sentivera in $1.5B+ Deal

Shots: Haisco has entered into an exclusive licensing agreement with Sentivera to develop, manufacture, & commercialize one of its preclinical immunology assets globally, excl. Greater China, in a deal valued at more than $1.5 billion. The agreement incl. $75.89M in upfront payment & equity consideration, ~$1.46B in development, regulatory & commercial milestones, plus tiered royalties…
August 26, 2026

Read more

NEWS

IntraGel Therapeutics and UroGen Pharma Ink Strategic Collaboration &  Investment to Advance TumoCure & Expand Sustained-Release Oncology Pipeline

Shots: IntraGel Therapeutics has entered into a strategic collaboration and investment agreement with UroGen Pharma to advance TumoCure for advanced head and neck cancer and expand the potential application of its SRGel biodegradable sustained-release platform As per the deal, UroGen will invest up to $7M in IntraGel to support the P-II development of TumoCure and…
August 21, 2026

Read more

NEWS

Avricore Health’s HealthTab Enters Multi-Year Collaboration with Abbott to Expand Point-of-Care Testing Across the UK

Shots: Avricore Health’s HealthTab entered a multi-year collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products through the HealthTab platform across the UK, supporting the expansion of pharmacy-based testing. Under the agreement, HealthTab will distribute Abbott’s Afinion 2 Analyzer through NHS-linked pharmacies for HbA1c and lipid profile testing, while establishing a framework…
August 20, 2026

Read more

NEWS

DeepCyte Launches AI Toxicology Atlas to Predict Drug Safety Risks

Shots: DeepCyte has launched DeeTox Atlas, the first single-cell metabolomic reference atlas for drug toxicity mechanisms, with enterprise pilots set to begin soon & three of the top 20 pharma companies already in pilot discussions Platform is built from 2 independent studies covering ~100 toxicant compounds, 300k cells & ~500 metabolites/cell, generating 3,000+ single-cell measurements…
August 19, 2026

Read more

NEWS

VectorBuilder and Lir Therapeutics Partner to Develop AAV Capsids

Shots: VectorBuilder & Lir have collaborated to develop AAV capsids, leveraging VectorBuilder’s DeepCap platform & expertise & Lir’s nAAVigator AI platform Lir will use its platform & lab-in-the-loop workflow to enhance capsids discovered through DeepCap, targeting higher productivity, full-capsid yield, quality, robustness, lower doses, & greater tissue specificity with reduced off-target delivery & immune recognition …
August 19, 2026

Read more

Load more